Genmab — December 2019
-
Mon ikke det har kostet hoveder ? https://www.bloomberg.com/news/articles/2019-04-05/aqr-head-of-machine-learning-set-to-leave-after-less-than-a-year
-
En rigtig god julehistorie (17.12) fra en (Don) vi G- mappere har fulgt i flere år. “Not Dead Yet
Not even close, doing pretty well actually” MM siden 2003 og skriver mere: “I've been on Pomalyst (Pom) since March of 2008, with the exception of one year when the Pom trial ended. Trials of three different experimental regimens failed me then, but Darzalex became approved and the combo of Darzalex, Pom, and dexamethasone (dex) brought my numbers way back down“
-
Myeloma Hope
Minnesota Don discusses treatments for multiple myeloma and his own experiences with them.
(myelomahope.blogspot.com)
-
innovaTV 207 adds a second arm, looks like a more precise dosing schedule. Adds 50 patients to 250. https://clinicaltrials.gov/ct2/history/NCT03485209?A=25&B=26&C=merged#StudyPageTop
-
Fra RBC 2020 Biotech outlook https://twitter.com/syinvesting/status/1208749029322088448
-
Lidt om CureVac og mRNA https://www.labiotech.eu/medical/curevac-genmab-mrna-antibody-cancer
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind